Q1 EPS Forecast for Oncolytics Biotech Increased by Analyst

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Investment analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a note issued to investors on Friday, April 10th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.03) per share for the quarter, up from their previous forecast of ($0.06). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech’s Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS, FY2026 earnings at ($0.12) EPS, FY2027 earnings at ($0.07) EPS, FY2028 earnings at ($0.08) EPS and FY2029 earnings at ($0.07) EPS.

Oncolytics Biotech (NASDAQ:ONCY) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02).

A number of other analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Oncolytics Biotech in a research report on Friday, March 27th. Wall Street Zen raised Oncolytics Biotech from a “strong sell” rating to a “hold” rating in a research report on Saturday, April 4th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Oncolytics Biotech has an average rating of “Moderate Buy” and an average price target of $8.50.

Oncolytics Biotech Stock Down 2.9%

Shares of NASDAQ ONCY opened at $1.02 on Tuesday. The stock has a market cap of $118.45 million, a PE ratio of -3.52 and a beta of 0.98. Oncolytics Biotech has a 52-week low of $0.33 and a 52-week high of $1.51. The business has a 50-day moving average price of $0.97 and a 200 day moving average price of $1.04.

Institutional Trading of Oncolytics Biotech

Several institutional investors and hedge funds have recently added to or reduced their stakes in ONCY. Scientech Research LLC purchased a new stake in Oncolytics Biotech during the 3rd quarter valued at approximately $25,000. Blair William & Co. IL purchased a new stake in shares of Oncolytics Biotech in the fourth quarter valued at about $28,000. Security National Bank of Sioux City Iowa IA acquired a new position in shares of Oncolytics Biotech during the fourth quarter worth about $29,000. Ground Swell Capital LLC acquired a new position in shares of Oncolytics Biotech during the fourth quarter worth about $30,000. Finally, CIBC Private Wealth Group LLC acquired a new position in shares of Oncolytics Biotech during the fourth quarter worth about $44,000. 6.82% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Patricia S. Andrews acquired 35,400 shares of Oncolytics Biotech stock in a transaction on Thursday, February 12th. The stock was purchased at an average cost of $0.86 per share, with a total value of $30,444.00. Following the purchase, the director directly owned 78,128 shares in the company, valued at approximately $67,190.08. The trade was a 82.85% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Andrew Aromando acquired 29,600 shares of Oncolytics Biotech stock in a transaction on Wednesday, February 11th. The shares were bought at an average cost of $0.86 per share, with a total value of $25,456.00. Following the completion of the purchase, the insider owned 55,100 shares in the company, valued at $47,386. The trade was a 116.08% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought 404,282 shares of company stock valued at $363,232 in the last quarter. 0.10% of the stock is currently owned by insiders.

Trending Headlines about Oncolytics Biotech

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: HC Wainwright materially narrowed expected full‑year 2026 losses to ($0.12) from a prior ($0.25), implying better near‑term financial outlook and less dilution/financing pressure than previously modeled. Q1 Earnings Forecast for ONCY Issued By HC Wainwright
• Positive Sentiment: HC Wainwright raised FY2027 and FY2028 EPS forecasts (FY2027 to ($0.07) from ($0.23); FY2028 to ($0.08) from ($0.22)), signalling an improved medium‑term recovery trajectory for the company. Q1 Earnings Forecast for ONCY Issued By HC Wainwright
• Positive Sentiment: Quarterly 2026 estimates were raised across Q1–Q4 to about ($0.03) per quarter (from deeper losses previously), which supports the FY2026 improvement and reduces short‑term cash burn concerns in analysts’ models. Q1 Earnings Forecast for ONCY Issued By HC Wainwright
• Neutral Sentiment: Consensus full‑year earnings expectations (~($0.28)) remain more negative than HC Wainwright’s improved 2026 forecast, so broader market expectations have not fully shifted yet. Q1 Earnings Forecast for ONCY Issued By HC Wainwright
• Negative Sentiment: HC Wainwright trimmed its FY2029 outlook (to ($0.07) from ($0.04)), a deterioration that signals uncertainty about longer‑term commercialization or revenue ramps and could cap upside for the stock. Q1 Earnings Forecast for ONCY Issued By HC Wainwright

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.